Glycema Tablet

Introduction

Glycema Tablet 5 mg is a medication used primarily in the management of type 2 diabetes mellitus. It belongs to the class of drugs known as SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors), which help to lower blood glucose levels through a unique mechanism of action. Dapagliflozin is typically used in conjunction with diet and exercise to improve glycemic control.

Uses

Glycema Tablet 5 mg is used for:

Type 2 Diabetes Mellitus: It is prescribed to help control blood sugar levels in adults with type 2 diabetes. It can be used alone or in combination with other antidiabetic medications.
Chronic Kidney Disease: In certain cases, it is used to slow the progression of chronic kidney disease in patients with type 2 diabetes.
Heart Failure: It may also be used to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and other heart conditions.

The medication is part of a comprehensive treatment plan that includes lifestyle modifications.

Brand Name	Glycema
Type	Tablet
Weight	5 mg
Generic	Dapagliflozin Propanediol
Manufacturer	ACI Limited
Available in	English বাংলা

Mechanism of Action

Glycema Tablet 5 mg works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys. SGLT2 is responsible for reabsorbing glucose from the urine back into the blood. By blocking this transporter, dapagliflozin reduces glucose reabsorption, leading to increased glucose excretion in the urine and consequently lowering blood glucose levels.

How Long Does It Take to Work?

Initial effects on blood glucose levels can typically be seen within 1 to 2 weeks of starting dapagliflozin treatment. Optimal glycemic control may take several weeks to fully establish. Individual responses can vary based on factors such as dosage and the patient’s overall health condition.

Absorption

Dapagliflozin is rapidly absorbed after oral administration. The maximum plasma concentration is generally achieved within 1 to 2 hours. Food intake does not significantly affect the absorption of dapagliflozin.

Route of Elimination

Dapagliflozin is primarily eliminated through the urine, with approximately 75% of the dose excreted as unchanged drug. The remainder is metabolized in the liver and excreted via the urine. The drug’s half-life supports once-daily dosing.

Dosage

Adults: The recommended starting dose of Dapagliflozin is 5 mg once daily, taken in the morning, with or without food. In patients tolerating Dapagliflozin 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily. Patients with Renal Impairment: Assessment of renal function is recommended prior to initiation of Dapagliflozin therapy and periodically thereafter. Dapagliflozin should not be initiated in patients with an eGFR less than 60 mL/min/1.73 m². No dose adjustment is needed in patients with mild renal impairment (eGFR of 60 mL/min/1.73 m² or greater). Dapagliflozin should be discontinued when eGFR is persistently less than 60 mL/min/1.73 m².

Children: The safety and efficacy of Dapagliflozin in children and adolescents (<18 years) have not been established.

The typical dosage for dapagliflozin is 5 mg to 10 mg once daily, depending on the patient's condition and response. Dosage adjustments may be necessary based on individual factors such as kidney function and other concurrent medications. Always follow the specific dosing instructions provided by a healthcare provider.

Administration

Dapagliflozin is administered orally in the form of tablets. It can be taken with or without food. For best results, take the medication at the same time each day to maintain consistent blood levels. Follow the dosage and administration instructions provided by your healthcare provider.

Side Effects

Common side effects of dapagliflozin may include:

Genital infections
Urinary tract infections
Increased urination
Thirst

Serious side effects may include ketoacidosis, severe urinary tract infections, and kidney problems. If any severe or unusual symptoms occur, seek medical attention immediately.

Toxicity

Overdose of dapagliflozin is unlikely to cause severe toxicity, but it may exacerbate side effects such as dehydration or urinary tract infections. In case of overdose, supportive measures and symptomatic treatment should be provided. Contact a healthcare provider for guidance.

Precautions

Precautions include:

Monitor for signs of ketoacidosis, especially in patients with type 1 diabetes or those with insulin deficiency.
Use with caution in patients with renal impairment, as dose adjustments may be required.
Ensure adequate hydration to prevent dehydration.

Regular monitoring of blood glucose levels and kidney function is recommended.

Interaction

Dapagliflozin may interact with other medications, including:

Diuretics: Increased risk of dehydration and hypotension.
Insulin or insulin secretagogues: Risk of hypoglycemia when used in combination with other glucose-lowering agents.

Inform your healthcare provider of all medications and supplements you are taking to avoid potential interactions.

Disease Interaction

Be cautious when using dapagliflozin in patients with:

Renal impairment or history of kidney disease.
History of urinary tract infections or genital infections.
Heart failure or other cardiovascular conditions.

Regular monitoring and adjustments may be necessary based on disease progression and overall health.

Drug Interaction

Drug interactions may include:

Medications that affect kidney function or diuretics.
Other antidiabetic drugs that may lead to additive effects on blood glucose levels.

Always consult with a healthcare provider to manage potential interactions and adjust treatment as needed.

Food Interactions

There are no significant food interactions with dapagliflozin. It can be taken with or without food. However, maintaining a balanced diet and proper hydration is important for optimal treatment outcomes and overall health.

Pregnancy Use

Dapagliflozin is not recommended during pregnancy due to potential risks to the developing fetus. The drug’s effects on pregnancy are not well-studied, and alternative treatments should be considered for managing diabetes during pregnancy. Consult a healthcare provider for appropriate management options.

Lactation Use

The use of dapagliflozin during lactation is not well-studied. It is unknown whether the drug is excreted in human milk or its effects on a breastfeeding infant. Use with caution and consult a healthcare provider to weigh the benefits and risks before using this medication while breastfeeding.

Acute Overdose

In case of acute overdose, symptoms may include severe dehydration and hypotension. Supportive care and symptomatic treatment are recommended. Contact a healthcare provider or poison control center for immediate guidance and management.

Contraindication

Dapagliflozin is contraindicated in:

Patients with severe renal impairment (e.g., eGFR <30 mL/min/1.73 m²).
Patients with a history of serious hypersensitivity reactions to dapagliflozin.

Ensure to evaluate all contraindications before initiating treatment.

Use Direction

Take dapagliflozin exactly as prescribed by your healthcare provider. Follow the dosage instructions and take the medication at the same time each day. Adhere to any dietary or lifestyle recommendations provided to optimize the medication’s effectiveness.

Storage Conditions

Store dapagliflozin tablets at room temperature, between 20°C to 25°C (68°F to 77°F). Keep the medication in its original container, tightly closed, and out of reach of children. Avoid storing in excessive heat or moisture.

Volume of Distribution

The volume of distribution of dapagliflozin is approximately 73 L, indicating distribution beyond the blood plasma into body tissues. The drug is primarily concentrated in the kidneys, where its action takes place.

Half Life

The elimination half-life of dapagliflozin is approximately 12.9 hours, supporting its once-daily dosing regimen. This half-life allows for sustained glucose-lowering effects over a 24-hour period.

Clearance

Dapagliflozin is cleared mainly through the urine. The drug’s clearance is influenced by renal function; impaired renal function may reduce the clearance rate and necessitate dose adjustments.

See in details version Glycema Tablet 5 mg also Glycema Tablet 5 mg in bangla